-
Road to SLAS 2024
Nagi Bioscience sets road to SLAS 2024 to connect with researchers and professionals, explore partnerships, and establish the basis of Nagi’s expansion plan.
-
Nagi Bioscience raises 12.4MCHF Series A round
Nagi Bioscience is thrilled to announce the successful closure of its Series A funding round co-led by Swisscanto and imec.xpand.
-
Nagi Bioscience takes the stage at EUROTOX 2023
SydLab™ One visits Ljubljana for EUROTOX 2023 to unlock the potential of micro-organisms for DART studie
-
About worms, NAMs and DART studies at WC12
Some thoughts of Nagi’s CSO Laurent Mouchiroud on NAMs in DART studies. Speaker at WC12 Niagara Falls.
-
A ‘Parts List’ for cancer’s spread: Worms to fight metastasis
C. elegans and the quest against cancer metastasis.
-
Nagi presents SydLab™ one at Worm23
Nagi Bioscience showcased its new solution for C. elegans testing – SydLab™ One – at the recently concluded 24th International C. elegans Conference in Glasgow.
-
Canada takes a step towards ending animal testing
In a significant move towards ethical scientific practices, Canada has taken a decisive step to ban the testing of toxic chemicals on animals.
-
3D-printed conductive circuits into C. elegans worms
C. elegans worms have become the first living organism into which a 3D-printed conductive circuit has been successfully done
-
Nagi Bioscience receives the Innosuisse Certificate accrediting for sustainable growth
“This certification accredits that Nagi is fully ready to start scaling-up as commercial organization and to accomplish our mission of accelerating the transition to a new era of biological testing with our state-of-the-art technology.”
-
Nagi Bioscience has been selected for SLAS Innovation AveNew 2023
Nagi Bioscience has been selected for the prestigious SLAS Innovation AveNEW 2023 cohort.